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Abstract 
The differential diagnosis between chondroma and intraosseous chondrosarcoma is based on imaging and clinical 
exams, but only a biopsy can confirm diagnosis. The aim of this study was to evaluate the value of PET–CT in differen‑
tially diagnosing chondroma and chondrosarcoma. From October 2009 to May 2015, 36 patients with cartilaginous 
bone lesions in the extremities, 12 (33.3 %) men and 24 (66.6 %) women, were prospectively included in the study. 
Patients ranged in age from 21 to 68 years, with a mean age of 44 years. Lesions were located in the long bones: in 
the proximal humerus in 26 (72.2 %) patients, in the femoral shaft in 1 (2.7 %), in the distal femur in 7 (19.4 %), and in 
the proximal tibia in 2 (5.5 %). The SUVmax value of 2.0 was used to separate between patients submitted to surgery 
and patients submitted to observation. Among the 36 patients studied, 17 (47.2 %) had SUVmax ≤ 2.0, and they were 
diagnosed as chondroma and they were treated conservatively. Follow‑up ranged from 14 to 76 months, averag‑
ing 38 months. Nineteen (52.7 %) patients with SUVmax >2.0 were diagnosed as chondrosarcoma and underwent 
surgery. The area of the curve, calculated considering the SUV variable as numeric, is estimated in 0.966, with a 95 % 
confidence interval from 0.906 to 1.000. To evaluate the sensitivity, specificity and positive/negative predictive values, 
it was built a 2 × 2 table. Significance was set at p < 0.05. According the criteria of maximum sensitivity and specific‑
ity, the cut point suggested to SUVmax was 2.2. If we consider this point, it is possible to identify 19 of 36 positive 
cases to chondroma (52.8 %), it means, all chondrosarcomas of the series. We concluded that PET–CT can be used as 
an objective and quantitative method of differentiating between chondromas and chondrosarcomas located within 
the long bones. It represents a complementary examination to standard imaging (X‑ray, scintigraphy, CT and MRI) and 
pathological exams. The SUVmax between 2.0 and 2.2 would be a range area between chondroma and chondrosar‑
coma and this range can be of value, among others exams, in decide the best treatment for patients with cartilagi‑
nous lesions in long bones.
Level of evidence Level I—diagnostic study—prospectively investigating a diagnostic test using a universally applied 
“gold” standard.
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Background
The differential diagnosis of intraosseous cartilaginous 
lesions is based on imaging or clinical examination find-
ings. Chondroma is a benign variant, characterized by 
the formation of mature hyaline cartilage without atypia, 
while chondrosarcoma is a malignant tumor that pro-
duces atypical cartilage matrix and features an infiltrative 
growth pattern in the medullary and cortical bone tissue.
The differential diagnosis between benign and malig-
nant variants based on imaging is not reliable and often 
results in false negatives or false positives (Rosenthal 
et al. 1984).
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One option to avoid false results is to conduct a biopsy 
of the tumor for pathological analysis. However, samples 
collected from a single area of the lesion are not repre-
sentative of the entire lesion, since the tumor may have 
niches of malignant transformation into chondrosarcoma 
next to areas of morphologically benign cartilage.
Another issue to consider when doing a biopsy is that 
histologically differentiating between chondromas and 
low-grade chondrosarcomas may be difficult even for 
experienced pathologists, mainly because differentiation 
is observer-dependent, especially when only a small tis-
sue sample is available (Evans et  al. 1977; Mankin et  al. 
2006).
Image-guided biopsies in patients with cartilage 
lesions have a low accuracy of 85.9  % (Jennings et  al. 
2010). When we compare the diagnosis based on the 
biopsy and the histological final grade after studying the 
whole tumor, we usually find a high rate of discrepancies 
(Kumar et al. 1993; Olszewski et al. 1983).
Studies on the use of PET–CT in the study of sarco-
mas began to appear after 2001 (Al-Ibraheem et al. 2013; 
Aoki et  al. 2001, 2003; Benz et  al. 2009, 2010; Brenner 
et  al. 2004; Eary et  al. 1998, 2002; Feldman et  al. 2005; 
Folpe et al. 2000; Garcia et al. 1996; Purandare et al. 2009; 
Schulte et al. 1999). Some authors suggested that because 
PET–CT detects hyper metabolic foci, that whole body 
PET–CT could be an important test for identifying chon-
drosarcomas and their recurrence after surgery. Charest 
et  al. (2009) retrospectively evaluated the sensitivity of 
PET–CT in the diagnosis of sarcomas of bone and soft 
tissue and established a SUVmax score of 2.5 as the 
threshold between low and high-grade sarcomas, with an 
accuracy of 94 %.
In 2005, Feldman et  al. (2005) studied the applica-
tions of PET–CT in the differential diagnosis between 
29 benign and malignant cartilaginous lesions and used 
a “cutoff” of SUV = 2.0. The SUVmax was >3.3 in grade 
I chondrosarcomas, >5.4 in grade II and >7.1 in grade III 
chondrosarcomas. They found the method to have high 
sensitivity, specificity and accuracy. They concluded that 
an SUV value >2.0 was a suspected malignancy (with 
91 % sensitivity; Feldman et al. 2005).
Benz et al. (2009, 2010) studied the accuracy and sen-
sitivity of PET–CT in evaluating the response of sarco-
mas to neoadjuvant treatment and found that the best 
responders showed greater declines in SUV levels relative 
to poor responders. These authors concluded that PET–
CT could accurately detect lymph nodes and metastases 
in patients with sarcomas (Benz et al. 2009, 2010)
Despite previous publications evaluating PET–CT in 
chondrosarcomas and in sarcomas in general, we found 
no study evaluating PET–CT in the differential diagno-
sis between chondromas and chondrosarcomas with the 
aim of determining whether tumor removal should be 
indicated.
We conducted a prospective study comparing the sen-
sitivity and accuracy as well as the false positive and false 
negative rates of PET–CT in patients with cartilaginous 
tumors in the appendicular skeleton.
The aim of this study was to evaluate the validity of 
PET–CT as a method for the differential diagnosis 
between chondroma and chondrosarcoma in patients 
with cartilaginous neoplasms of long bones.
Results
Among all 36 patients, 17 (47.2 %) with SUVmax scores 
≤2.0 were submitted to PET–CT and diagnosed, by the 
PET–CT interpretation, as chondroma. These patients 
were not submitted to surgery. Nineteen (52.8 %) patients 
had a SUVmax > 2.0 and were diagnosed, by the PET–CT 
interpretation, as chondrosarcoma. These patients were 
submitted to surgery.
The result of the pathological examination showed that 
among the 19 (52.8 %) patients, with SUVmax > 2.0, 18 
(50.0 %) were confirmed as chondrosarcoma grade I and 
1 (2.7 %) patient did not confirm the PET–CT results and 
had the final diagnosis as chondroma.
At the last follow-up, no patients among the 17, not 
submitted to surgery, had evidence of lesion progression, 
which supported the diagnosis of chondroma.
When we analyzed the pathologic results in light of 
the PET–CT findings, we found 1 chondrosarcoma 
among the 17 patients with SUVmax  ≤  2.0, (Patient 
# 29, SUVmax =  2.0). On the other hand, we found 18 
(50.0  %) chondrosarcomas and 1 (2.7  %) chondroma on 
the pathology analysis, among the 19 patients with SUV-
max > 2.0 (Table 1).
During follow-up of at least 14 months (14–76 months, 
medium = 40 months), to patients with chondroma diag-
nosis, we observed no cases of progression of the lesion, 
based on MRI and clinical evaluation.
The accuracy of the SUVmax in the differentiation 
between chondroma and chondrosarcoma was evaluated, 
concerning the numeric value, by a ROC curve. The sta-
tistical analysis, concerning the categorical variable, was 
Table 1 SUVmax in  patients with  and without  surgical 
indication relative to results obtained in the last follow-up
Golden standard (anatomopathological report or last follow‑up)





Positive (>2.0) 18 1 19
Negative (≤2.0) 1 16 17
Total 19 17 36
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evaluated among the true positives, true negatives, false 
positives and false negatives values. The measure of accu-
racy, sensitivity, specificity, prevalence, and the predictive 
positive and negative were evaluated and followed in the 
confidence range of 95 %.
The diagnosis based on anatomopathological examina-
tion or in the follow up presented 19 (52.8 %) among 36 
cases as chondrosarcoma. One of the patients with diag-
nosis of chondroma, was submitted to surgery. When 
we consider the value of SUVmax bigger than 2.0, it was 
possible to identify 18 among 36 cases positive to chon-
drosarcoma (63.9  %). One patient had the diagnosis of 
chondroma.
The area of the curve, calculated considering the SUV 
variable as numeric, is estimated in 0.966, with a 95  % 
confidence interval from 0.906 to 1.000. To evaluate the 
sensitivity, specificity and positive/negative predictive 
values, we built a 2 × 2 table. Kappa agreement was com-
puted using the SPSS statistical package and significance 
was set at p < 0.05. According the criteria of maximum 
sensitivity and specificity, the cut point suggested to 
SUVmax was 2.2. If we consider this point, it is possible 
to identify 19 of 36 positive cases to chondroma (52.8 %), 
it means, all chondrosarcomas of the series.
The measures of diagnostic adequacy were calculated 
considering the two points of cut. They were presented 
in the Table  2. They indicate the method as more sen-
sible than specific. But, the range of the confidence 
interval indicate that more patients will be necessary to 
evaluate the SUVmax as a tool to discriminate the chon-
droma versus chondrosarcomas patients (Landis and 
Koch 1977).
Discussion
The differential diagnosis between chondroma and chon-
drosarcoma remains one of the toughest in Orthopedics 
Oncology. We prospectively studied the validity of PET–
CT for this purpose.
When we analyze the differences between chondroma 
and chondrosarcoma we found non specific symptoms 
and the clinical and orthopedic examination are often 
normal or uncharacteristic.
The X-ray and CT scan provides good definition images 
of cartilage, but sometimes, are unable to differentiate 
between benign and malignant cartilage. X-ray and CT 
are very useful for the analysis of cortical bone invasion 
and periosteal reaction by the tumor. If there is invasion, 
it is most likely that the lesion is a chondrosarcoma and 
not a chondroma, but most of the times, the findings 
unfortunately are inconclusive.
Skeletal scintigraphy with technetium reveals a slight 
increase in concentration in chondromas. The concentra-
tion is greater in chondrosarcoma lesions, particularly in 
the more peripheral areas of an active lesion, which cause 
erosion and cortical bone reaction. However, because 
these are slow-growing lesions, even in the case of chon-
drosarcomas, bone destruction, which causes neogenesis, 
is small.
In MRI, chondromas present with low or medium sig-
nal on T1-weighted sequences and high signal on T2 
sequences. The erosion and remodeling of cortical bone 
and extra-cortical involvement appear clearly. Injection 
of gadolinium increases the signal, but sometimes, even 
with contrast, it is difficult to differentiate between chon-
droma and chondrosarcoma (Aoki et al. 1991; Som et al. 
1980).
These methods are not a 100 % precise, and interpreta-
tion can vary among expert radiologists (Skeletal Lesions 
Interobserver Correlation among Expert Diagnosticians 
(SLICED) Study Group 2007). Often, the radiologist 
emits an inconclusive report of “compatible with chon-
droma or chondrosarcoma” or a report of “cartilaginous 
lesion”.
For the definitive anatomopathological diagnosis differ-
entiating chondroma and chondrosarcoma, all available 
information must be considered (patient age, presence of 
pain, history of rapid growth, lesion location, size of the 
lesion, radiographic, CT, magnetic resonance and scintig-
raphy image). However, the cartilaginous tumor biopsy is 
controversial and currently most bone tumor reference 
centers do not perform it. The cartilaginous tumor is het-
erogeneous in its presentation and biopsy sampling of a 
region may not represent a significant area of the tumor.
Histological staging is the most important topic regard-
ing the evolution of the biological behavior of chondro-
sarcoma and is mainly based on cellularity and atypia 
or the presence of bizarre morphology of the cells (Aoki 
et  al. 1991; Brien et  al. 1997; Lee et  al. 1999; Sundaram 
and McLeod 1990).





True positives 19 18
False positives 4 1
False negatives 0 1
True negatives 13 16
Prevalence by SUV 63.9 % (46.2–79.2 %) 52.8 % (35.5–69.6 %)
Real Prevalence 52.8 % (35.5–69.6 %) 52.8 % (35.5–69.6 %)
Sensitivity 100.0 % (75.1–100.0 %) 94.7 % (74.0–99.9 %)
Specificity 76.5 % (50.1–93.2 %) 94.1 % (71.3–99.9 %)
Positive predictive value 82.6 % (61.2–95.0 %) 94.7 % (74.0–99.9 %)
Negative predictive value 100.0 % (66.1–100.0 %) 94.1 % (71.3–99.9 %)
Accuracy 88.9 % (73.9–96.9 %) 94.4 % (81.3–99.3 %)
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We understand that a weak point of this analysis is to 
define the golden standard as the anatomopathological 
report. We know that the reliability of the grading of car-
tilaginous neoplasm, even among specialized and expe-
rienced pathologists is critical, but our analysis, is based 
on Evans criteria, as a protocol in our Institution, and we 
believe there is no important bias in the interpretation 
(Evans et  al. 1977; Skeletal Lesions Interobserver Cor-
relation among Expert Diagnosticians (SLICED) Study 
Group 2007).
Several signaling pathways have been shown to be 
affected in central cartilaginous neoplasms: RB1 and 
TP53, cytogenetic alterations and mutations in the IDH1 
and IDH2 genes, as well as the analysis of DNA ploidy by 
cytofluorometry, which has improved the knowledge of 
the origin and real nature of this type of lesion. However, 
these findings do not yet translate into useful diagnostic 
tools for the differential diagnosis between chondroma 
and chondrosarcoma, which would be possible only after 
tumor resection (Aoki et al. 2003; Brien et al. 1997; Brien 
et al. 1999).
Under these circumstances, and considering the doubts 
raised by the imaging findings, we decided to comple-
ment the workup with the use of PET–CT.
PET–CT has the ability to measure the avidity of malig-
nant cells by glucose, since the intracellular transport 
of glucose labeled with 18-FDG ([18F] Fluoro-2-deoxy-
d-glucose) is higher in malignant cells. The low perme-
ability of the membrane limits the back-diffusion of FDG 
during the examination, keeping the FDG within the 
malignant cells, which allows for their detection (Schulte 
et al. 1999).
Based on evidence in the literature showing that it is 
possible to differentiate benign lesions with low SUV-
max from malignant lesions with high SUVmax, we con-
ducted a prospective evaluation of intraosseous cartilage 
lesions of long bones (Dehdashti et  al. 1996; Eary et  al. 
2011; Kern et  al. 1988; Schulte et  al. 2000). We limited 
our evaluation to intra osseous lesions in humerus, femur 
and tibia. We defined the value of the uptake of radioac-
tive fluorine-labeled glucose as SUVmax  =  2.0 for the 
dividing line between patients whose will be submitted 
to surgical treatment supposed to be chondrosarcomas 
and patients without surgical treatment, supposed to be 
chondromas (Feldman et al. 2005).
Unique properties of cartilage (e.g., small cellularity, 
very low rate of mitosis, high quantities of chondroid 
matrix and inactive extracellular matrix, poor vasculari-
zation and anaerobic glycolysis) contribute to low SUV 
values. Even in vascularized or aggressive cartilaginous 
lesions, SUV levels rarely reach the levels of sarcomas 
with a different histogenesis, such as osteosarcomas, 
fibrosarcomas or Ewing’s tumor (Brenner et  al. 2004; 
Schulte et al. 2000). Because of this, grade I and II chon-
drosarcomas, regardless of size, amount of calcification 
or necrosis areas, have a low SUV, reflecting glucose 
metabolism.
We agree with Brenner et  al. (2004) that the metabo-
lism of the tumor, in terms of metabolic activity and 
oncologic behavior, is characterized by SUVmax. The 
area with the highest SUV reflects the area in the tumor 
with the highest metabolic activity (which represents 
the most aggressive area of the lesion), and it is this area 
that should be used for tumor classification, treatment 
decisions and prognosis. This area is the site of greatest 
activity in the lesion, regardless of tumor size or shape. 
Moreover, SUVmax allows for a better comparison 
between different devices and services, as it does not 
depend on the definition of the volume or shape of the 
ROI, which is examiner-dependent. We believe that the 
SUVmax, obtained manually inside the ROI placed over 
the tumor, is the measure of greatest reproducibility.
The literature shows that SUVmax values for the dif-
ferentiation between benign and malignant tumors vary 
between 1.3 and 4.0 across Institutions and publications, 
due to the different equipment and protocols used, as 
well as differences in lesion histology (Eary and Conrad 
2011; Eary et al. 2002).
Although we used a value of SUVmax in our study, we 
believe that the dividing line between chondroma and 
chondrosarcoma should be a range of SUVmax scores 
and not a cutoff line, with a specific SUVmax value. If 
we have used the SUVmax ≥ 2.2 it would be possible to 
detect 18 among the 19 cases of chondrosarcoma and 16 
among the 17 cases of chondroma. It was demonstrated 
in the Table 2. The best option would be considering the 
range between SUVmax = 2.0 and 2.2 as an intermediate 
area when we use the PET–CT to differentiate the chon-
droma from the chondrosarcoma.
Some variables can alter the assessment of cartilage 
lesion SUV, such as small size, the time between injec-
tion and the start of the test, the duration of the test post-
injection, the amount of glucose in the patient’s blood, 
patient weight and body surface area. The small number 
of patients and the short follow-up time of patients not 
undergoing surgery may represent a weak point in our 
conclusions, but we believe that our results nevertheless 
open a new perspective on the noninvasive diagnosis of 
cartilaginous tumors.
We also believe that creating a score that incorporates 
data from the clinical examination as well as X-ray, CT, 
MRI, scintigraphy and PET–CT could increase diagnos-
tic accuracy.
Treatment for chondromas is different from that for 
chondrosarcomas. Benign cartilaginous lesions can be 
treated conservatively. When we face a chondrosarcoma, 
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the curettage plus cryotherapy and cementation or wide 
resection would be the most frequent options of treat-
ment. We have to consider the possibility of the progres-
sion of the cancer cells inside the medullary canal and 
destruction of the cortical bone reaching the soft tissue, 
with a chance of progressing to the extra-cortical com-
partment and invading the soft tissue as well as metasta-
sizing to the lungs. Early diagnosis of chondrosarcoma is 
important in oncological practice.
One point that may be questioned in our study is the 
fact that we did not perform histopathology on benign 
tumors, those who had the SUVmax  ≤  2.0, and only 
conducted follow-up for at least 14  months. Follow-up 
without a anatomopathological exam may lead to false 
negatives, which can only be clarified with a longer follow-
up. However, biopsies of cartilage lesions also would lead 
to a high number of false negatives, which could also rep-
resent a fragile and ethically questionable point in a study 
such as this one. In addition to the risk of implantation of 
cartilaginous cells during the biopsy, there are risks asso-
ciated with anesthesia, infection and the hospital costs for 
the biopsy and anatomopathological examination.
PET–CT is not without risks, as it involves the injec-
tion of contrast as well as some radiation from the 
tomography. Thus, we suggest that, in the future, the CT 
scan should be limited to the area with bone changes in 
order to limit the amount of radiation to the site being 
studied. However, this would not allow us to conduct a 
comprehensive staging of the patient, including a CT 
scan of the chest, which is important in the case of chon-
drosarcomas. PET–CT is a costly procedure that is not 
yet available in all Hospitals, but has the potential to soon 
become an important tool in the differentiation between 
chondroma and chondrosarcoma.
The confidence interval of this study was relatively large 
(which is most likely due to the small sample size). Fur-
ther studies with a more robust sample size are needed.
We believe that a larger number of patients will allow us to 
confirm or not, if the use PET–CT, to differentiate between 
patients with cartilaginous lesions, who require surgical 
treatment from those who do not is a method of value.
Conclusions
PET–CT can be used as an objective and quantitative 
method of differentiating between chondromas and 
chondrosarcomas located within the long bones. It rep-
resents a complementary examination to standard imag-
ing (X-Ray, scintigraphy, CT and MRI) and pathological 
exams. The SUVmax between 2.0 and 2.2 would be a 
range area between chondroma and chondrosarcoma 
and can be of value, among others exams, in decide the 
best treatment for patients with cartilaginous lesions in 
long bones.
Methods
The study was submitted and approved by the Ethics 
Committee of the Institution and all patients gave their 
writing consent to participate in this prospective study.
From October 2009 to May 2015, 36 patients with 
cartilage lesions detected through imaging were staged 
using X-rays, CT, MRI and PET–CT (Table 3). Twenty-
four (66.6 %) patients were female and 12 (33.3 %) were 
male, with a mean age of 44.0 (range 21–68). Lesions 
were located in the long bones: in the proximal humerus 
in 26 (72.2 %) patients, in the femoral shaft in 1 (2.7 %), 
in the distal femur in 7 (19.4 %), and in the proximal tibia 
in 2 (5.5  %). All patients were submitted to X-rays, CT, 
scintigraphy, and an MRI and were then sent for PET–
CT scan.
PET–CT was performed in all patients during the stag-
ing period. Patients underwent a preparation with a low-
carbohydrate diet for 12 h before the test and fasted for 
4 h (but could drink water). Patients had their blood glu-
cose measured before injection of the radioactive tracer 
and all results were below 180  mg/dL. Sixty to ninety 
minutes before the start of the study, they received an 
intravenous injection of 0.1  mCi/kg (3.7  MBq/kg) 18F-
FDG and remained at rest in a quiet environment during 
the period of accumulation.
The images were obtained with hybrid PET–CT equip-
ment. Until May of 2012, tests were performed with 
Discovery ST (General Electric—USA) equipment, with 
3D acquisition, 4 min per FOV and reconstruction with 
Ultra HD-PET with 2 iterations and 21 “subsets”. After 
May of 2012, scans were performed with the Biograph 
mCT 40 PET–CT machine (Siemens Medical Solutions, 
USA), 3D acquisition, 3 min per FOV and Ultra HD-PET 
reconstruction with 2 iterations and 21 subsets. On both 
equipment, CT was conducted before PET, scanning 
from the skull to the distal femur (extending to the whole 
body in cases of lesions below the knee) with low doses 
of radiation and applying attenuation correction. On the 
Discovery ST-GE equipment, the irradiation dose used 
was 120 kV and on the Biograph mCT 40 Siemens equip-
ment, it was 100 kV. In both equipment, radiation beam 
modulation was applied.
All tests were processed at the same workstation, the 
Syngo.via (Siemens Medical Solutions, USA), with PET–
CT software. We performed an automatic volumetric 
region of interest (VOI) in the chondral lesion in order to 
obtain the automatic SUV value (40 % threshold) of the 
region of interest. The analysis was redone in some situ-
ations, for instance, when the automatic VOI included 
degenerative changes with increased glycolytic activity 
(when the lesion was close to joints), shifting the area 
of interest. We thus avoided including this region in the 
analysis (Fig. 1).
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Among the 36 study patients, 17 (47.2  %) had SUV-
max  ≤  2.0. Follow-up ranged from 14 to 76  months, 
with a mean of 38 months. Sixteen of these patients were 
treated conservatively (without surgery) and their follow-
up was done only with MRI every 6 months during the 
first 2  years and once a year from the third to the fifth 
years. No patient among them presented tumor pro-
gression or metastasis during the follow-up period. One 
patient (Pat.#29), with SUVmax = 2.0, but with an MRI 
reported as chondrosarcoma was submitted to surgery.
The 19 (52.7 %) patients with SUVmax > 2.0 underwent 
surgery. The tumor removed during surgery was sent for 
pathological examination. The material was fixed in a 
10 % formalin solution, decalcified with 15 % nitric acid, 
subjected to routine histology and stained with hema-
toxylin and eosin. According to the current literature, the 
criteria used for histologic diagnosis are based on lesion 
cellularity, the presence of permeation of the cortical 
and/or cancellous bone tissue, cytological atypia and the 
presence of myxoid degeneration in the matrix (Evans 
et al. 1977).
 The follow-up of the patients submitted to surgery was 
done with X-rays and MRI every 6  months during the 
first 2  years and once a year from the third to the fifth 
years. No patient present local recurrence or metastasis 
in the follow-up period.
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